Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;137(1):315-8.
doi: 10.1007/s10549-012-2345-5. Epub 2012 Nov 27.

The penetrance of ductal carcinoma in situ among BRCA1 and BRCA2 mutation carriers

Affiliations

The penetrance of ductal carcinoma in situ among BRCA1 and BRCA2 mutation carriers

Emanuele Mazzola et al. Breast Cancer Res Treat. 2013 Jan.

Abstract

Ductal carcinoma in situ (DCIS) is a precancerous lesion of the female breast and is strongly suspected to be a precursor of invasive breast cancer (IBC). Our goal is the estimation of the age-specific and lifetime penetrances of DCIS among carriers of either a BRCA1 or BRCA2 deleterious mutation. We jointly re-analyze the SEER9 database and a previous study by Claus et al. (JAMA 293:964-969, 2005). Estimation is performed via Bayes theorem after the evaluation of the ratio of age-specific DCIS incidences, and extrapolation to the general population of the study-specific penetrance obtained from Claus et al. From the SEER9 database, we estimate the lifetime risk of DCIS to be 0.98 %, in contrast to value of 12.5 % usually reported for IBC. By extending the result in Claus et al. to the general population, we obtain a lifetime risk for carriers of a deleterious mutation of either BRCA1 or BRCA2 of 6.21 % (95 % CI 6.09-6.33 %). The increase in lifetime risk of DCIS for a BRCA mutation carrier compared to a non-carrier is therefore about six-fold. Our quantification is directly relevant to the identification and genetic counseling of BRCA mutation carriers, and emphasizes the potential importance of including information on diagnoses of DCIS in counseling of individuals who are at familial risk for breast cancer. All these factors can contribute to a more specific and targeted prevention, potentially reducing the impact of IBC among BRCA mutation carriers.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
The curves QSEER(a) and PSEER(a) after rescaling to achieve a lifetime probability of invasive breast cancer equal to the well known value of 0.125 [14]. Consistently, by maintaining fixed the empirical ratio between age-specific risks for IBC and DCIS from the original curves, we are able to obtain the lifetime risk of DCIS in the general population
Fig. 2
Fig. 2
The curves PClaus(a|B), r(a) and PSEER(a|B) and the data used to estimate them. PClaus(a|B) is the age-specific penetrance of DCIS for mutation carriers estimated from the data in Claus study [8]. The points in the same color are positioned at the ages for the cases, and their height corresponds to the frequencies obtained estimating the parameters of a gamma distribution via maximum-likelihood method; the interpolating curve is the complete estimated density. The curve PSEER(a|B) is the estimated age-specific penetrance for DCIS in the carrier population. The areas under the solid lines are equal to 0.0079 and 0.0621. They represent, respectively, the estimates of the lifetime risk of being diagnosed with DCIS for a woman participating in study [8] and the lifetime risk for the carrier population overall. The gray-shaded area is the 95 % bootstrap confidence interval for the age-specific penetrance for the carrier population. Also graphed are curve r(a) and the SEER-based empirical ratios used to estimate it
Fig. 3
Fig. 3
The curves PSEER(a), or the age specific risk for DCIS in the general population, and PSEER(a|B) or the age-specific risk for carriers of a BRCA mutation in the general population. The gray-shaded area is the 95 % bootstrap confidence interval for the age-specific penetrance for the carrier population

References

    1. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336(20):1401–1408. - PubMed
    1. Ford D, Easton DF, Bishop DT, et al. Breast Cancer Linkage Consortium: risks of cancer in BRCA1 mutation carriers. Lancet. 1994;343(8899):692–695. - PubMed
    1. Easton DF, Ford D. Bishop DT Breast and ovarian cancer incidence in BRCA1 mutation carriers: Breast Linkage Consortium. Am J Hum Genet. 1995;56(1):265–271. - PMC - PubMed
    1. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: the Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3):676–689. - PMC - PubMed
    1. Thorlacius S, Struewing JP, Hartge P, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet. 1998;352:1337–1339. - PubMed

Publication types